propafenone

(redirected from Rythmol)

propafenone

 [pro″pah-fe´nōn]
a sodium channel blocking agent that acts on the Purkinje fibers and the myocardium; used as the hydrochloride salt in treatment of life-threatening arrhythmias, administered orally.

propafenone

/pro·pa·fe·none/ (pro″pah-fe´nōn) a sodium channel blocking agent acting on the Purkinje fibers and the myocardium; used as the hydrochloride salt as an antiarrhythmic.

propafenone

Rythmol® Cardiology A beta-blocking antiarrhythmic for severe ventricular and supraventricular arrhythmias–A Fib, V Tach, conduction block, HTN Complications Ventricular proarrhythmia; conduction defects Adverse effects Neurologic–headache, dizziness, paresthesias, peripheral neuropathy, GI–eg, N&V, anorexia. See Antiarrhythmic, Beta-blockers.

propafenone

A drug used to treat heart irregularities (arrhythmias). A brand name is Arythmol.

propafenone (prō´pəfē´nōn),

n brand name: Rythmol;
drug class: antidysrhythmic (Class IC);
action: able to slow conduction velocity; reduces cardiac muscle membrane responsiveness; inhibits automaticity; increases ratio of effective refractory period to action potential duration; β-blocking activity;
use: documented life-threatening dysrhythmias.
References in periodicals archive ?
On January 3, 2011, Par Pharmaceutical successfully launched the 225mg, 325mg, and 425mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline's Rythmol SR [R] .
Linde predicted that if the new REVERSE findings are confirmed in the much larger ongoing Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT) trial and Rythmol SR Atrial Fibrillation Trial (RAFT), as she expects, the indications for CRT will broaden to incorporate the large population of patients with class I and II heart failure.
for infringement of United States Patent 5,681,588, which expires in 2014 and relates to Reliant's Rythmol SR product.
GlobalData's pharmaceuticals report, Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022 provides Rythmol SR global sales estimates.
Reliant Pharmaceuticals, LLC (Liberty Corner, NJ), a privately held, rapidly growing pharmaceutical company that markets branded, patent-protected pharmaceutical products in the United States, announced that it has signed a definitive agreement to acquire the United States rights to the Rythmol (propafenone HCl) product family from Abbott Laboratories.
Drug treatments include Cordarone (amiodarone), Corvert (ibutilide), Tambocor (flecainide), Rythmol (propafenone), Cardioquine (quinidine), Betapace (sotalol) and Tikosyn (dofetilide).
Angotti led the expansion of a mass market and specialty sales force in the United States to promote both Lovaza, a treatment for hypertriglyceridemia, and Rythmol SR, a treatment for atrial fibrillation.
Driscoll has been directly involved in multiple major transactions including such products as Lovaza[TM] and Rythmol SR[R].
These guidelines point to Rythmol SR as an appropriate first-line antiarrhythmic treatment option within the revised treatment paradigm," he added.
Par Pharmaceutical remained the exclusive supplier of generic Rythmol SR[sup.
com announces that a new market research report is available in its catalogue: Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022 http://www.
NYSE: PRX) today announced that it began shipping the 225mg, 325mg, and 425mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline's Rythmol SR.